Valuation: Avadel Pharmaceuticals plc

Market Cap 2.12B 1.86B 1.72B 1.59B 3.01B 203B 3.07B 20.68B 8.03B 99.53B 7.98B 7.8B 345B P/E 2024
-20.5x
P/E 2025 33.7x
Enterprise Value 2B 1.75B 1.62B 1.49B 2.83B 191B 2.89B 19.42B 7.55B 93.49B 7.49B 7.33B 325B EV / Sales 2024
5.78x
EV / Sales 2025 7.12x
Free-Float
99.5%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Avadel Pharmaceuticals plc

1 day+0.05%
6 months+0.74%
Current year+0.42%
Current year 21.4
Extreme 21.395
21.76
1 year 9.43
Extreme 9.43
23.57
3 years 6.38
Extreme 6.38
23.57
5 years 6.38
Extreme 6.38
23.57
10 years 6.38
Extreme 6.38
23.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2020-12-06
Chief Tech/Sci/R&D Officer - 2019-12-01
Investor Relations Contact - -
Date Insider Type Main position Quantity % Market Cap.
02-12
Weiss Asset Management LP
SellCompany 11,112,052 11.3600%
02-11Issuer sale

Chief Executive Officer

3,091,105 3.1601%
02-11Issuer sale

Chief Financial Officer

1,104,900 1.1296%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-.--%+139.38% - 2.12B
-1.60%+2.02%+56.34%+168.94% 1,084B
-1.44%+3.71%+69.07%+65.40% 634B
-0.75%+0.67%+33.18%+86.52% 447B
-0.45%-2.28%+28.35%+25.81% 330B
-9.68%-11.05%+24.80%+27.03% 295B
-0.65%-2.11%+28.47%+46.09% 285B
-0.97%-3.55%-27.73%-39.69% 218B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
Average -1.27%+2.27%+39.81%+58.99% 366.2B
Weighted average by Cap. -0.90%+2.48%+40.21%+85.17%

Financials

2024 2025
Net sales 169M 148M 137M 127M 240M 16.19B 245M 1.65B 640M 7.92B 635M 621M 27.51B 279M 245M 226M 209M 396M 26.73B 404M 2.72B 1.06B 13.08B 1.05B 1.03B 45.41B
Net income -48.83M -42.83M -39.54M -36.54M -69.26M -4.68B -70.65M -475M -185M -2.29B -183M -179M -7.94B 64.67M 56.72M 52.37M 48.39M 91.72M 6.19B 93.56M 630M 245M 3.03B 243M 238M 10.52B
Net Debt -34.93M -30.64M -28.29M -26.14M -49.55M -3.34B -50.54M -340M -132M -1.64B -131M -128M -5.68B -129M -113M -104M -96.45M -183M -12.34B -186M -1.25B -488M -6.04B -484M -473M -20.97B
Logo Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Employees
188
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. AVDL Stock